Novel transcatheter heart valve may be effective for management of high-risk aortic regurgitation

1. The 30-day composite primary safety endpoint of > 40.5% was achieved for Trilogy TAVI. 2. 8% of patients who underwent Trilogy TAVI had passed at the 1-year follow-up. Evidence Rating Level: 1 (Excellent) Study Rundown: Surgery remains the primary intervention for native aortic regurgitation, but high-risk patients lack optimal alternatives. Traditional transcatheter heart valves

Related Keywords

,Jenavalve Technology ,Rating Level ,Surgical Treatment ,Between Jun ,Cardiac Surgery ,Cardiology ,Heart Valves ,Prosthetic Valves ,Tavr ,Transcatheter Aortic Valve Implantation ,Transcatheter Aortic Valve Replacement Tavr ,Valvular Disease ,Chronic Disease ,Imaging And Intervention ,Surgery ,